SK80697A3 - Use of mhc-ii binding molecules - Google Patents

Use of mhc-ii binding molecules Download PDF

Info

Publication number
SK80697A3
SK80697A3 SK806-97A SK80697A SK80697A3 SK 80697 A3 SK80697 A3 SK 80697A3 SK 80697 A SK80697 A SK 80697A SK 80697 A3 SK80697 A3 SK 80697A3
Authority
SK
Slovakia
Prior art keywords
mhc
molecules
lps
cell
diseases
Prior art date
Application number
SK806-97A
Other languages
English (en)
Slovak (sk)
Inventor
Roger P Lauener
Original Assignee
Om Lab Sa
Deutsche Om Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Lab Sa, Deutsche Om Arzneimittel Gmbh filed Critical Om Lab Sa
Publication of SK80697A3 publication Critical patent/SK80697A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
SK806-97A 1994-12-23 1995-12-27 Use of mhc-ii binding molecules SK80697A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203755 1994-12-23
PCT/EP1995/005164 WO1996020215A2 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases

Publications (1)

Publication Number Publication Date
SK80697A3 true SK80697A3 (en) 1997-12-10

Family

ID=8217495

Family Applications (1)

Application Number Title Priority Date Filing Date
SK806-97A SK80697A3 (en) 1994-12-23 1995-12-27 Use of mhc-ii binding molecules

Country Status (11)

Country Link
EP (1) EP0800534A2 (cs)
JP (1) JPH10511652A (cs)
CN (1) CN1171117A (cs)
AU (1) AU4347696A (cs)
BR (1) BR9510554A (cs)
CA (1) CA2208233A1 (cs)
CZ (1) CZ186897A3 (cs)
HU (1) HUT77468A (cs)
PL (1) PL320922A1 (cs)
SK (1) SK80697A3 (cs)
WO (1) WO1996020215A2 (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
US5817757A (en) * 1995-10-30 1998-10-06 Merck & Co., Inc. Inhibitors of peptide binding to MHO class II proteins
US5840835A (en) * 1995-10-30 1998-11-24 Merck & Co., Inc. Inhibitors of peptide binding to MHC class II proteins
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
GB0201896D0 (en) * 2002-01-28 2002-03-13 Ice Biolog Ltd Treatment
CA2452986C (en) * 2001-07-02 2011-11-01 Aimsco Limited Use of polyclonal anti-hiv goat serum as a therapeutic agent
WO2003064472A2 (en) * 2002-01-28 2003-08-07 Aimsco Limited Treatment of ms with goat serum
ES2232273B1 (es) * 2003-03-21 2006-07-16 Jose Manuel Fernandez-Real Lemos Nuevas aplicaciones terapeuticas de la glucoproteina cd14s.
EP2266606B1 (en) * 2003-05-15 2014-09-10 Genentech, Inc. Methods and compositions for the prevention and treatment of sepsis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0068790B1 (en) * 1981-06-25 1986-02-26 The Board Of Trustees Of The Leland Stanford Junior University Allele specific immunotherapeutic method and dosage form
GB8310403D0 (en) * 1983-04-18 1983-05-25 Mach B F Cotransformed mouse cells
JPS6225994A (ja) * 1985-05-30 1987-02-03 ジエネテイツク　システムズ　コ−ポレイシヨン Ｈｌａタイプ分け用モノクロ−ナル抗体
JPS63275526A (ja) * 1987-05-03 1988-11-14 Hiroshi Okajima Ｈｉｖウイルス中和抗体
FR2658197B1 (fr) * 1990-02-14 1992-05-22 Inst Nat Sante Rech Med Anticorps monoclonaux restreints reconnaissant un peptide associe a un antigene du complexe majeur d'histocompatibilite - applications au diagnostic et au traitement.
DE4029227A1 (de) * 1990-09-14 1992-03-19 Imtox Gmbh Arzneimittel enthaltend cd14
AU3220593A (en) * 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
EP0634935A4 (en) * 1992-04-06 1996-01-31 North Shore Univ Hospital A NEW THERAPY OF SEPSIS BY MEANS OF A SOLUBLE FORM OF RECOMBINANT CD14 MYELOMONOCYTIC ANTIGEN.
ATE223485T1 (de) * 1992-10-15 2002-09-15 Toray Industries Verfahren zur herstellung von rekombinant mhcii protein in mikroorganismen
US5820858A (en) * 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies

Also Published As

Publication number Publication date
CN1171117A (zh) 1998-01-21
BR9510554A (pt) 1999-06-29
AU4347696A (en) 1996-07-19
WO1996020215A2 (en) 1996-07-04
PL320922A1 (en) 1997-11-10
CA2208233A1 (en) 1996-07-04
EP0800534A2 (en) 1997-10-15
HUT77468A (hu) 1998-05-28
CZ186897A3 (cs) 1998-03-18
WO1996020215A3 (en) 1996-10-10
JPH10511652A (ja) 1998-11-10

Similar Documents

Publication Publication Date Title
Sanyal et al. MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells
Suda et al. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing
Schmid et al. Inherited defects in lymphocyte cytotoxic activity
Weinstein et al. Lipopolysaccharide-induced protein tyrosine phosphorylation in human macrophages is mediated by CD14.
Asavapanumas et al. Unique neuromyelitis optica pathology produced in naive rats by intracerebral administration of NMO-IgG
Glas et al. Recruitment and activation of natural killer (NK) cells in vivo determined by the target cell phenotype: an adaptive component of NK cell–mediated responses
Romani et al. The exploitation of distinct recognition receptors in dendritic cells determines the full range of host immune relationships with Candida albicans
Coutelier et al. B lymphocyte and macrophage expression of carcinoembryonic antigen‐related adhesion molecules that serve as receptors for murine coronavirus
EP3630158B1 (en) Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
SK80697A3 (en) Use of mhc-ii binding molecules
Allenbach et al. An essential role for transmembrane TNF in the resolution of the inflammatory lesion induced by Leishmania major infection
Aravindhan et al. Cell type-specific immunomodulation induced by helminthes: effect on metainflammation, insulin resistance and type-2 diabetes
Bánki et al. Antibody opsonization enhances MAIT cell responsiveness to bacteria via a TNF‐dependent mechanism
Kissner et al. Activation of MyD88 signaling upon staphylococcal enterotoxin binding to MHC class II molecules
CN113621077B (zh) 一种tim-3/cd28融合蛋白及所述融合蛋白修饰的car-t细胞
AU2020363993B2 (en) Compositions and methods for treating cytotoxic T cell resistant tumors
JP2025069165A (ja) 耐性を誘導するための操作された細胞
EP1367393A1 (en) Methods for using the CD 163 pathway for modulating an immune response
Palermo et al. Fcγ receptor‐dependent clearance is enhanced following lipopolysaccharide in vivo treatment
AU6316799A (en) Use of MCH-II binding and/or MHC-II mimicking molecules for the prevention and/or treatment of inflammatory diseases
JP2016069314A (ja) 免疫抑制剤
US10588941B2 (en) Modulation of CCR10 signals for treatment of skin and intestinal inflammatory diseases and infection
Song Hu5F9 anti-CD47 antibody promotes macrophage phagocytosis of SIV-infected cells in various infection stages
Müller-Eberhard et al. Molecular mechanisms of cytotoxicity: comparison of complement and killer lymphocytes
Tweedle TNF Antagonism Stifles Host Response to Pulmonary Pathogen through Gut/lung Immunoregulatory Axis